The FDA has granted accelerated approval to Tudriqev, a new melanoma treatment that works for patients whose cancer has stopped responding to standard immunotherapy. This approval marks a significant shift for a group of patients who have historically faced limited options. About half of melanoma patients don't respond to checkpoint inhibitor drugs in the first place, and more than half of those who do respond eventually see their cancer progress again.

How Does Tudriqev Work Differently From Standard Melanoma Treatments?

Tudriqev takes a fundamentally different approach to fighting melanoma compared to the immunotherapy drugs that have become the standard first line of defense. Rather than relying on a systemic infusion, the treatment is injected directly into melanoma lesions, including tumors deep within the body, using imaging to guide the injection. The drug itself is built from a modified virus designed to target tumor cells while simultaneously prompting the immune system to fight the cancer more broadly.

Once injected, Tudriqev is paired with nivolumab, a checkpoint inhibitor drug sold under the brand name Opdivo. Checkpoint inhibitors work by removing the brakes that cancer cells place on the immune system, allowing the body's natural defenses to recognize and attack malignant cells. The combination of the injected virus and the checkpoint inhibitor creates a two-pronged attack that appears to work even when standard immunotherapy alone has failed.

What Do the Clinical Trial Results Show?

The approval was based on data from a clinical trial that evaluated 91 patients with advanced melanoma that had continued to progress despite prior treatment. The results were modest but meaningful for this difficult-to-treat population. Among the 91 patients studied, 24.2 percent responded to the Tudriqev and nivolumab combination, and for those who did respond, the response lasted a median of 14.1 months.

One particularly encouraging finding was that the therapy worked on tumors that hadn't been directly injected, not just the lesions that received the treatment. This suggests that the localized injection triggers a broader immune response throughout the body, a phenomenon researchers call the "abscopal effect".

"The therapy in combination with nivolumab drives immune activation with a favorable risk-benefit profile, and can be injected into superficial and visceral lesions," said Michael K. Wong, MD, PhD, the primary investigator of the study.

Michael K. Wong, MD, PhD, Primary Investigator of the Study

What Are the Side Effects and Safety Considerations?

For patients considering Tudriqev, understanding the safety profile is essential. The most common side effects were mild to moderate and included nausea, fatigue, and injection site reactions. However, serious side effects did occur in some patients, and the treatment carries warnings around infection risk because it's built on a modified virus.

The infection risk is particularly important for patients to discuss with their oncologists, as it reflects the nature of the treatment itself. Because the therapy uses a modified virus to trigger immune activation, there is an inherent risk that the virus could cause infection in some cases. This is a trade-off that patients and doctors must weigh against the benefit of having a treatment option for melanoma that has resisted standard immunotherapy.

Steps to Take If You're Considering Tudriqev

• Discuss Prior Treatments: Have a detailed conversation with your oncologist about which immunotherapies you've already tried and how your cancer responded, since Tudriqev is specifically designed for patients whose melanoma has progressed despite prior treatment.
• Understand the Injection Process: Ask your doctor about how the injections are performed, including how imaging guidance is used to target lesions deep in the body and what to expect during and after the procedure.
• Review Side Effect Management: Work with your medical team to develop a plan for managing potential side effects like nausea and fatigue, and establish clear protocols for monitoring infection risk throughout treatment.
• Clarify Response Expectations: Discuss realistic outcomes based on the trial data, including the 24.2 percent response rate and the median 14.1-month duration of response for patients who do respond.

Why Does This Approval Matter for Melanoma Patients?

Melanoma remains a serious public health challenge in the United States. It is the fifth most common cancer in the country, and every year more than 8,500 people die of melanoma. For decades, treatment options for patients whose cancer resisted standard immunotherapy were severely limited, often forcing doctors and patients to consider chemotherapy or clinical trials as their only alternatives.

"Every year, more than 8,500 people die of melanoma in the U.S., and new treatment options are urgently needed," said Sam Guild, president of AIM at Melanoma.

Sam Guild, President of AIM at Melanoma

Tudriqev represents a meaningful step forward for patients who have exhausted standard immunotherapy options. Unlike another round of systemic infusions, which can be taxing on the body and may not work for patients whose cancer has already shown resistance, Tudriqev is delivered directly into the tumor. This localized approach, combined with the systemic immune activation it triggers, offers something that has been in short supply for this population: a second-line option built specifically for their situation.

The accelerated approval pathway used for Tudriqev reflects the FDA's recognition that this treatment addresses an unmet medical need. Patients with advanced melanoma that has progressed despite prior immunotherapy have few good options, and the agency determined that the evidence of benefit was sufficient to warrant approval even as additional data continues to be collected.